The RESOLUTE phase III trial of AstraZeneca’s Fasenra (benralizumab), despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic ...

Saphnelo, which generated $304 million in sales in the first half of this year, is projected to achieve peak annual sales of ...

AstraZeneca ( NASDAQ: AZN) said that the late-stage trial for its medication Fasenra (benralizumab) in patients suffering ...

Starting next year, citizens aged 56 and 66 will be able to receive pulmonary function tests as part of the National Health ...

A father's exposure to passive smoking as a child may impair the lifelong lung function of his children, putting them at risk of chronic obstructive pulmonary disease.

AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and ...

A major global study published in The Lancet has found that while deaths from chronic diseases such as cancer, heart disease, ...

Patients are increasingly turning to ChatGPT for medical advice, but new research warns it isn’t yet accurate enough to be relied on alone.

AstraZeneca (AZN) announced on Wednesday that its late-stage trial of Fasenra in patients with chronic obstructive pulmonary ...

According to a recent report by Mordor Intelligence, the ventilators market is valued at USD 5.38 billion in 2025 and is projected to surpass USD 7.42 billion by 2030, registering a CAGR of 6.6% ...

Innovaccer has acquired AI-powered platform Story Health to lead the development of AI agents that enhance speciality care ...

Each of us takes about 20,000 breaths every single day—20,000 chances for the air around us to either sustain life or to ...